Citius Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CITIUS PHARMS, and when can generic versions of CITIUS PHARMS drugs launch?
CITIUS PHARMS has one approved drug.
There is one US patent protecting CITIUS PHARMS drugs.
There are two patent family members on CITIUS PHARMS drugs in two countries and one supplementary protection certificate in one country.
Summary for Citius Pharms
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Citius Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | DISCN | No | No | 8,440,170 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | DISCN | No | No | 8,440,170 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | DISCN | No | No | 8,440,170 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Citius Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | 6,149,938 | ⤷ Sign Up |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | 6,149,938 | ⤷ Sign Up |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | 6,149,938 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CITIUS PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Orally Disintegrating Tablets | 15 mg and 30 mg | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Orally Disintegrating Tablets | 37.5 mg | ➤ Subscribe | 2013-03-22 |
International Patents for Citius Pharms Drugs
Supplementary Protection Certificates for Citius Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2317997 | 2190050-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
